December 04, 2016 6:12 PM ET

Biotechnology

Company Overview of Acceleron Pharma, Inc.

Key Executives for Acceleron Pharma, Inc.

NameBoard RelationshipsTitleAge
John L. Knopf Ph.D.12 RelationshipsCo-Founder, Chief Executive Officer, President and Director64
Thomas P. Maniatis Ph.D.25 RelationshipsCo-Founder, Chairman of Scientific Advisory Board, Director and Member of Compensation Committee73
Mark Ptashne Ph.D.29 RelationshipsCo-Founder and Member of Scientific Advisory Board--
Kevin F. McLaughlin 9 RelationshipsChief Financial Officer, Senior Vice President and Treasurer60
Steven D. Ertel No RelationshipsChief Operating Officer and Executive Vice President47
View More Key Executives

Acceleron Pharma, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Francois Nader M.D., M.B.A. 56 RelationshipsNPS Allelix, Corp.59
John L. Knopf Ph.D. 12 RelationshipsAcceleron Pharma, Inc.64
Thomas P. Maniatis Ph.D. 25 RelationshipsAcceleron Pharma, Inc.73
Mark Ptashne Ph.D. 29 RelationshipsAcceleron Pharma, Inc.--
Jean M. George 60 RelationshipsLightstone Ventures58
View All Board Members

Acceleron Pharma, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Terrence C. Kearney31 Relationships3 Executives
Compensation Committee Joseph S. Zakrzewski80 Relationships3 Executives
Nominating Committee Jean M. George60 Relationships3 Executives
Corporate Governance Committee Jean M. George60 Relationships3 Executives
Advisory Board Ph.D.Thomas P. Maniatis25 Relationships4 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$532.7K
532.7K
377.6K
Bonus$4.1M
4.1M
261.1K
Total Short Term Compensation$532.7K
532.7K
471.8K
Total Value of Options
33.3M
Compensation as of Fiscal Year
Acceleron Pharma, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Calimmune Appoints Dr. Salim Yazji as EVP and Chief Medical Officer
November 26, 2016 8:27 AM ET
Vasopharm Names Irina Antonijevic as New Chief Medical Officer
November 25, 2016 12:28 PM ET
Alchemia Limited Announces Resignation of Nathan Drona as Non-Executive Director
November 24, 2016 10:15 PM ET
Shree Ganesh Bio-Tech (India) Limited Announces Management Changes
November 24, 2016 12:15 PM ET
Invitrocue Appoints Ramanuj Dasgupta as Senior Scientific Director, Effective December 1, 2016
November 23, 2016 10:53 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Acceleron Pharma, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.